甲泼尼龙琥珀酸钠治疗儿童难治性肺炎支原体肺炎临床观察

Clinical observation of methylprednisolone in treatment of refractory mycoplasma pneumoniae pneumonia in children

目的探讨甲泼尼龙琥珀酸钠治疗儿童难治性肺炎支原体肺炎(RMPP)的临床疗效及对C-反应蛋白(CRP)水平的影响。方法将45例RMPP患儿随机分为治疗组和对照组,在常规治疗基础上,治疗组给予甲泼尼龙琥珀酸钠2 mg/(kg·d),对照组给予地塞米松0.25 mg/(kg·d)。评价两组临床疗效及治疗前后CRP水平变化。结果治疗组退热时间、咳嗽缓解时间均短于对照组(P<0.05);治疗组肺部炎症吸收率显著高于对照组(P<0.05);治疗组治疗后CRP水平较对照组改善明显(P<0.01)。两组均未发现药物相关不良反应。结论甲泼尼龙琥珀酸钠可有效改善RMPP患儿的临床症状、影像学表现及CRP水平,短期应用安全性好。

[ Objective ] To observe the therapeutic effect of the methylprednisolone in treatment of refractory mycoplasma pneumoniae pneumonia （RMPP） and the level change of C-reactive protein （CRP） in children. [ Methods ] 45 patients with RMPP were randomly assigned into the treatment group and the control group. Both groups were treated with conventional therapy,the patients in the treatment group were given methylprednisolone 2 mg/（kg · d）, while the patients in the control group were given dexamethasone 0.25 mg/（kg· d）. Clinical efficacy and the level of CRP in two groups were observed. [ Results ] The corrected time of fever and the relieved time of cough in the treatment group were less than in the control group （P〈0.05）; the pulmonary shadow disappearance rate in the treatment group was higher than in the control group （P〈0.05）; the level of CRP in the treatment group was significantly improved than in the control group（P〈0.01）; no significant adverse reactions were observed in all patients. [ Conclusion ] Application of methylprednisolone could effectively alleviate the symptom, the imaging manifestations and the level of CRP in RMPP patients, with a good security in short term.